Misplaced Pages

FV-100: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 20:33, 19 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit Latest revision as of 11:22, 27 December 2024 edit undoCitation bot (talk | contribs)Bots5,427,471 edits Added work. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar 
(34 intermediate revisions by 25 users not shown)
Line 1: Line 1:
{{Orphan|date=April 2011}}

{{chembox {{chembox
| Verifiedfields = changed
| verifiedrevid = 415900961 | verifiedrevid = 424911420
|ImageFile=Cf1743.png | ImageFile=Cf1743.png
|ImageSize=200px | ImageSize=200px
⚫ |IUPACName=3--6-(4-pentylphenyl)furopyrimidin-2-one
| IUPACName=3-(2-Deoxy-β-<small>D</small>-''erythro''-pentofuranosyl)-6-(4-pentylphenyl)furopyrimidin-2(3''H'')-one
⚫ |OtherNames=Cf1743
⚫ | SystematicName=3--6-(4-pentylphenyl)furopyrimidin-2(3''H'')-one
⚫ | OtherNames=Cf1743
|Section1={{Chembox Identifiers |Section1={{Chembox Identifiers
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=
| CASNo= 956483-02-6
⚫ | PubChem=493485
| ChEMBL = 344738
⚫ | SMILES=CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)4C((O4)CO)O
| ChemSpiderID = 431897
⚫ | PubChem=493485
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0NJ5F6D4U7
| StdInChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
| StdInChIKey = MFGSDSRTGUVZQG-DFQSSKMNSA-N
⚫ | SMILES=CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)4C((O4)CO)O
}} }}
|Section2={{Chembox Properties |Section2={{Chembox Properties
| C=22 | H=26 | N=2 | O=5 | C=22 | H=26 | N=2 | O=5
| Appearance= | Appearance=
| Density= | Density=
| MeltingPt= | MeltingPt=
| BoilingPt= | BoilingPt=
| Solubility= | Solubility=
}} }}
|Section3={{Chembox Hazards |Section3={{Chembox Hazards
| MainHazards= | MainHazards=
| FlashPt= | FlashPt=
| AutoignitionPt =
| Autoignition=
}} }}
}} }}


'''FV-100''', also known as '''Cf1743''', is an orally available nucleoside analogue drug<ref>{{cite |url=http://www.medicalnewstoday.com/articles/138537.php |title=Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies |year=2009 }}</ref> with antiviral activity.<ref>{{cite journal | doi = 10.1093/jac/dkp294 | author = McGuigan, Christopher; Balzarini, Jan | title = FV100 as a new approach for the possible treatment of varicella-zoster virus infection | journal = Journal of Antimicrobial Chemotherapy | year = 2009 | volume = 64 | issue = 4 | pages = 671–673 | pmid = 19679595}}</ref> It may be effective against ].<ref>{{cite |url=http://www.dailymail.co.uk/health/article-515969/Thousands-spared-pain-shingles.html |quote="And at Cardiff University, Chris McGuigan, professor of medicinal chemistry, has developed a new drug for shingles, FV-100, which is doing well in phase I trials. FV 100 looks like it will be very potent (more than 10,000 times as strong as aciclovir), safe and could prevent long-term pain, too. It could be on the market by 2010." |year=2010 }}</ref> '''FV-100''', also known as '''Cf1743''', is an orally available ] drug<ref>{{citation |url=http://www.medicalnewstoday.com/articles/138537.php |title=Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies |year=2009 }}</ref> with ] activity.<ref>{{cite journal | doi = 10.1093/jac/dkp294 |author1=McGuigan, Christopher |author2=Balzarini, Jan | title = FV100 as a new approach for the possible treatment of varicella-zoster virus infection | journal = ] | year = 2009 | volume = 64 | issue = 4 | pages = 671–673 | pmid = 19679595| doi-access = free }}</ref> It may be effective against ].<ref>Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. ''J Med Virol''. 2017 Jul;89(7):1255-1264. {{doi|10.1002/jmv.24750}} {{PMID|27943311}}</ref>


It was discovered in 1999.<ref>{{cite |url=http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html |title=Step forward for shingles drug - FV100 }} Shows structure of FV100</ref> It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.<ref>{{citation |url=http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html |title=Step forward for shingles drug - FV100. |author1=Cardiff School of Pharmacy |author2=Pharmaceutical Sciences }} Shows structure of FV100.</ref>


==Clinical trials== ==Clinical trials==
It is in a ] against ] in patients with ].<ref>{{cite |url=http://clinicaltrials.gov/ct2/show/NCT00900783 |title=A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster }}</ref> FV-100 was tested against ] in a ] in patients with ]. The trial was sponsored by Bristol-Myers Squibb.<ref>{{citation |url=http://clinicaltrials.gov/ct2/show/NCT00900783 |title=A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster |date=23 September 2015 }}</ref> The drug is currently being developed by , ].<ref>{{citation |url= http://www.dddmag.com/news/2015/01/contravir-pharmaceuticals-fda-meeting-about-antiviral-drug-trial?et_cid=4352306&et_rid=297252576&type=cta| title=ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.| work=Drug Discovery & Development| date=January 2015 }}</ref> It has reached Phase III clinical trials.<ref>De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. ''Clin Microbiol Rev''. 2016 Jul;29(3):695-747. {{doi|10.1128/CMR.00102-15}} {{PMID|27281742}}</ref>


==References== ==References==
{{reflist}} {{reflist}}


{{Antivirals}}

]
] ]
] ]
] ]
]




{{pharma-stub}} {{antiinfective-drug-stub}}

Latest revision as of 11:22, 27 December 2024

FV-100
Names
IUPAC name 3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furopyrimidin-2(3H)-one
Systematic IUPAC name 3--6-(4-pentylphenyl)furopyrimidin-2(3H)-one
Other names Cf1743
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1Key: MFGSDSRTGUVZQG-DFQSSKMNSA-N
SMILES
  • CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)4C((O4)CO)O
Properties
Chemical formula C22H26N2O5
Molar mass 398.459 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). ☒N verify (what is  ?) Infobox references
Chemical compound

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb. The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey. It has reached Phase III clinical trials.

References

  1. Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009
  2. McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy. 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
  3. Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. doi:10.1002/jmv.24750 PMID 27943311
  4. Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.
  5. A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015
  6. "ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.", Drug Discovery & Development, January 2015
  7. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi:10.1128/CMR.00102-15 PMID 27281742
DNA virus antivirals (primarily J05, also S01AD and D06BB)
Baltimore I
Herpesvirus
DNA-synthesis
inhibitor
TK activated
Purine analogue
Pyrimidine analogue
Not TK activated
Other
HPV/MC
Vaccinia
Poxviridae
Hepatitis B (VII)
Multiple/general
Nucleic acid inhibitors
Interferon
Multiple/unknown


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: